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Abstract 
 
Background: Several treatments have been suggested in shingles viral infection caused by  Varicella zoster 
virus that may lead to complications such as PHN (Post-herpetic neuralgia). Intradermal injection of botulinum 
toxin was shown with few side effects. This study evaluates the efficacy of intradermal injection of botulinum toxin 
in patients suffering from PHN. 
 
Methods: Fifteen patients suffering from PHN for more than1 month were enrolled. Data collected were patients' 
age, sex, and lesion site, the dermatome involved and the duration and severity of pain by visual analog scale 
(VAS). Botulinum (15 units /every 10 cm² of body involved) was injected intradermally. The patients were fol-
lowed 2, 14 and 30 days after injection.  
 
Results: Of participants, 6 were males and 9 females. The mean age was 60 years and the mean duration of 
neuralgia was 6.5 months. The mean VAS on day 2 was 6.4, on day 14 was 7.2 and after 30 days was 7.6. The 
overall pain after injection decreased but was not significant. 
 
Conclusion: It seems that intradermal injection of botulinum toxin decreases pain in PHN patients and this de-
crease is less prominent by passing time. 
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Introduction 
 
Zona  occurs  due  to  weakening  of  immune  system, 
increase  in  age,  morbidity,  chemotherapy,  etc.    Its 
prevalence in normal population less than 20 years is 
1/1000 and is 5-10 times higher in those above 80 
years  of  age.
1  Post-herpetic  neuralgia  (PHN)  is  the 
most common complication of zona which is more 
commonly  seen  in  the  elderly  population  than  the 
children. The frequency of zona in the population un-
der 60 years of age is 2%.
2 In a study by Oxman et 
al., the prevalence of zona between the age group 60-
69 years was reported to be 6.9% and in the popula-
tion above 70 years of age it was 18.5%.
3 
PHN  is  divided into  three  phases  of  acute  (first 
month after the onset of rash), sub-acute (one to four 
months after the onset) and chronic (> 4 months after 
the onset)
4 and mostly involves the trigeminal, cranial 
and thoracic nerves.
5 The pain caused by PHN is ei-
ther continuous with a burning sensation or alternat-
ing with stinging sensation.
6 Almost, 90% of the peo-
ple suffering from PHN show an unusual response to 
normal painless stimuli, i.e. they develop pain upon 
exposure to light and touch.
7 The pain and discomfort 
due to PHN can be so severe that sometimes it can 
lead  to  sleep  disturbances,  decreased  appetite,  and 
decreased  libido.
5  The  pain  can  be  so  severe  that 
might lead to suicide.  
One of the reasons for the constant pain months 
after zona infection is the increase in the number of P 
fibers and decrease in the number of the large nerve 
fibers which suppress the pain transmission.
8 One of 
the treatments recommended for PHN is the use of 
botulinum  toxin  type  A.  Few  studies  performed  in 
this  regard  have  shown  that  intradermal  injections 
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have analgesic effects on PHN patients. The problem 
arising during the treatment of PHN is that the medi-
cation prescribed should have few or no side effects 
and should not cause cognitive impairment in the pa-
tients
9,10 and most of patients suffering from PHN are 
elderly  and  have  other  comorbidities.  Treatment  of 
PHN with botulinum toxin type A has shown promise 
in the long term pain control without any cognitive 
side effects.
11 In this study, we aimed to evaluate the 
effects of botulinum toxin type A in PHN patients.  
 
 
Materials and Methods 
 
In this interventional study, 15 patients suffering from 
PHN  were  selected  using  simple  sampling  method. 
The patients were included if they were over 18 years 
of age, had developed PHN at least one month after 
the rash, had not used botulinum toxin type A previ-
ously, had no coagulopathies and localized infection, 
no history of allergy to analgesics, did not have any 
tumor at the site, did not have septicemia, were not 
pregnant or lactating, did not have psychiatric prob-
lems or mental retardation, did not use amino glyco-
sides, and did not suffer from myasthenia gravis.  
After selection of patients, required explanations 
regarding the features of the drug, method of injec-
tion, possible complications of injection, possible an-
algesic effects were provided for patients. A consent 
form  was  taken from  each  patient.  A  questionnaire 
was used including data on age, sex, address, chief 
complaint, site of lesions (rash), the dermatome in-
volved, duration of PHN and severity of symptoms 
determined through a Visual Analogue Scale (VAS) 
as a standard criteria for determining the severity of 
pain.
12 The selected cases had a past medical history 
of affliction with zona, had not responded to the rou-
tine  treatments for  disease,  and  had  referred to  the 
psychiatry and dermatology clinics of Shiraz Univer-
sity of Medical Sciences. 
Before starting the intradermal injection of botuli-
num toxin type A, 2% lidocaine gel was applied on 
the  site.  After applying  the  gel,  botulinum  toxin A 
specific for every patient was injected based on our 
selected pattern. Fifteen units of botulinum toxin A 
diluted with 2% lidocaine were injected intradermally 
per 10 cm
2 of the painful surface area using the sy-
ringes used for injecting insulin. For patients, botuli-
num toxin type A with the trade name of dysport was 
used and each vial of the toxin was diluted with 4 ml 
of 2% lidocaine. The amount of toxin was different 
for every patient depending upon the extent and site 
of the lesion. The patients were followed after 2, 14 
and 30 days and the leftover pain was measured using 
VAS. Injections of the toxin and the follow-ups were 
done  by  one  person.  All data  were  statistically  ana-
lyzed using SPSS software (Version15, Chicago, IL, 
USA). In order to measure the effects of the toxin, Re-
peated Measure ANOVA was used and 0.05 was con-
sidered as the significance level.  
 
 
Results 
 
Out of 15 patients, 6 were male and 9 were female. 
The minimum age was 50 years and the maximum 67 
years with the mean of 60 years. The minimum dura-
tion of PHN was 1 month and the maximum was 36 
months with the mean value and standard deviation of 
6.4±8.4. The dermatomes involved ranged from 2-7 
with a mean of 4 dermatomes. VAS was measured 
during the follow-up visits of the patients. On day 2, 
VAS was between 0-10 with the standard deviation of 
6.4±4.4. In the second week, it was measured to be 
between 0-10 with the standard deviation of 4.2±7.2. 
Similarly, VAS was measured in the fourth week with 
minimum and maximum values of 0-10 and standard 
deviation of 3.7±7.6. 
Figure 1 shows the changes in VAS after the injec-
tion of botulinum toxin on days 2, 14 and 30 after 
treatment.  Pain  decreased  in  patients  in  the  fourth 
week in comparison to the pre-treatment period which 
was not statistically significant (p=0.06). Pain on the 
second day (p=0.007), in the second week (p=0.02) 
and in the first month (p=0.03) showed a significant 
decline as compared to pre-treatment group. The se-
cond week, a slight increase was noticed in pain as 
compared to the second day (p=0.16). In the fourth 
week,  an  increase  in  pain  was  also  observed  when 
compared to the second day (p=0.06). Also, increase 
in pain in the fourth week as compared to the second 
week was not significant (p=0.13). 
 
 
Discussion  
 
The pain caused by PHN has a very complex mecha-
nism,  so  different  treatments  have  been  suggested 
including    routine  analgesics,  tricyclic  antidepres-
sants,  carbamazepine,  gabapantine,  perfenazine, 
haloperidol, phenophenazine, aspirin, narcotics, cog-
nitive techniques like relaxation, hypnotism and bio-Botulinum toxin in neuralgia 
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feedbacks,  and  invasive  techniques  like  surgery 
(blocking  the  nerve  supplying  that  dermatome  or 
stimulating the posterior spinal cord).
13-15 Using botu-
linum  toxin  for  treatment  of  neuralgias  is  a  recent 
technique which has been used for the treatment of 
migraine headaches,
16-20 tension headaches,
21-25 back 
aches,  and  myofacial  pain.
26,27  This  combination  of 
treatments can be useful in neuropathic and nocicep-
tive pain suppression.
28 
After  reactivation,  zona  causes  inflammation  of 
the posterior ganglionic roots along with changes in 
the nociceptive pathways with automatic discharges 
and decrease in the nerve transmission which leads to 
the neuropathic pain. On the other hand, the nervous 
system becomes very sensitive to pain and develops 
pain  even  when  in  contact  with  weak  stimuli.
6,29-31 
Allodynia pain may be due to neural contacts which 
transmit pain to the central nervous system. Hyperac-
tivity of the efferent fibers A-beta after the neuronal 
damage causes pain upon touch, and presynaptic af-
ferent fibers C causes automatic pain. The mechanism 
of allodynia is not clearly known yet.
32 Intradermal 
injection  of  botulinum  to  decrease  burning  central 
pain and allodynia involves the spinal cord. This drug 
decreases the neuropathic pain by affecting the periph-
ery and most probably decreasing the central sensitivi-
ty.
33 The analgesic pharmacological effect of intrader-
mal injection is due to the release of neurotransmitters 
like acetylcholine from the axon terminals of the motor 
neurons, parasympathetic neurons, presynaptic sympa-
thetic  neurons  and  post-ganglionic  parasympathetic 
neurons with different mechanisms.
34  
Intradermal injection of botulinum decreases the 
substances with nociceptive sensitivity. Studies have 
shown that nociceptive effect of the localized injec-
tion of botulinum toxin leads to the inhibition of the 
release  of  formalin-induced  glutamate,  P  substance 
and  calcitonin  gene-related  peptide  which  play  an 
important role in the inflammation of neurons.
35,28 On 
the whole, neuropathic analgesic effect of botulinum 
toxin on PHN is due to the direct effect on sensory 
neurons  and  indirect  effect  on  central  nervous  sys-
tem.
36 This study showed that intradermal injection of 
botulinum toxin decreases pain in PHN but its anal-
gesic effect lessens with the passage of time e.g. those 
who had received botulinium toxin, 2 weeks or one 
month before had experienced more pain as compared 
to those who received the injection just 2 days ago. 
One  month  after  the  injection,  the  patients  experi-
enced less pain and had better quality of life in com-
parison. Freund and Schwarts in a study done on 7 
patients who suffered from PHN showed that botuli-
num injections decreased pain too. These patients had 
pain in the trigeminal, thoracic and back regions. Be-
fore the injection, their mean VAS was 8 which de-
creased  to  5  after treatment. The  patients  who suf-
fered from trigeminal neuralgia had responded much 
better to the treatment.
37  
 
Fig. 1: Changes based on VAS, pain before the injection, the second day, second week and first month after the 
injection of botulinum toxin A 
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A study was done on an 80 year old male suffering 
from  PHN,  who  had  co-morbidities  like  coronary 
heart disease and heart failure. The oral medications 
given to the patient were not effective as they caused 
delirium and cognitive dysfunction. Intradermal botu-
linum injections were given which were very effec-
tive as they decreased the pain of the patient from 
VAS=10 to VAS=1 and the analgesic effect of the 
injection lasted for 52 days.
38 
Another study done on 3 patients suffering from 
PHN  showed  that  botulinum  injections  decreased 
VAS from 8 to 2 in the second week of the follow up. 
In the tenth week, pain increased as compared to the 
second  week  but  it  was  bearable.
39  Similarly,  Rusi 
Huete performed a study on an 83 year old female 
suffering  from  PHN.  She  had  received  botulinium 
toxin injection and showed a very good response to 
the treatment without any side effects.
40  
Considering the present and some previous studies 
done  on  the  effect  of  botulinum  toxin  in  patients 
suffering from PHN, it seems that there can be a de-
crease in pain in the first week. However, analgesic 
effects of botulinum toxin decrease gradually as the 
weeks pass by. Overall, the pain is less and more tol-
erable when compared to pre-treatment period. This 
problem was reported in all studies. Due to the low 
number of available eligible patients, control group 
was not included in this study and it is suggested that 
a random clinical trial should be performed in which 
a group of patients receive placebo so that the analge-
sic effects of botulinum in the treatment of PHN can 
be better evaluated.    
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